IDKmonitor® Ustekinumab total ADA ELISA

Article number: K 9667

Test-Category

ELISA

Pack size

96 Tests

Possible sample matrix and volumes

Plasma 25 µl
Serum 25 µl

Incubation periods

  1. 20 minutes
  2. 1 hour
  3. 1.5 hours
  4. 10-20 minutes

Indications

Regulatory Status

CE marked

Therapy with biologics is a very effective treatment option for patients suffering from chronic inflammatory diseases. However, there are patients who do not respond to this therapy (primary non-responders) or who develop antibodies against the active substance in the course of treatment (secondary non-responders), i.e. who develop a "resistance" to the specific therapeutic agent.
Therefore, regular monitoring of both the drug level and the formation of antibodies against the drug is important for optimising therapy and the associated long-term therapeutic success. Only through regular monitoring can a secondary therapy failure be recognised at an early stage and possibly prevented.

This might also be of interest